Form 4: Y-mAbs Therapeutics Director Laura Hamill Receives Significant Equity Grants

Y-mAbs Therapeutics, Inc. Director Laura Hamill was granted 25,080 restricted stock units and 33,450 stock options, aligning her interests with shareholders.

Summary

• Director Laura Hamill acquired 25,080 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 30, 2025, at a price of $0 per share, increasing her direct beneficial ownership to 30,905 shares.
• The RSUs were granted under the Issuer's 2018 Equity Incentive Plan and vest in full on the earlier of the first anniversary of the grant date (June 30, 2026) or the date immediately preceding the Issuer's annual meeting of stockholders held in 2026, subject to continued service.
• Additionally, Ms. Hamill was granted 33,450 Employee Stock Options on June 30, 2025, with an exercise price of $4.51 per share and an expiration date of June 30, 2035.
• These stock options were also granted pursuant to the Issuer's 2018 Equity Incentive Plan and vest in equal monthly installments until the first anniversary of the grant date (June 30, 2026), subject to continued service, and are exercisable immediately upon vesting.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it details equity grants to a director, which is a standard practice for aligning interests and incentivizing long-term performance. There are no negative implications or risks presented.

Positives

• The equity grants to Director Laura Hamill align her financial interests directly with those of Y-mAbs Therapeutics shareholders, incentivizing long-term performance and value creation.
• The grants are part of a standard compensation structure, indicating stability in corporate governance and a commitment to retaining key talent.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate an expectation of continued service from Director Laura Hamill, reinforcing her long-term commitment to Y-mAbs Therapeutics.

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, to directors is a common practice across the biotechnology and pharmaceutical industries. This approach is widely used to attract, retain, and incentivize experienced board members by aligning their financial success with the company's performance and shareholder value.

Comparison to Industry Standards

• The structure of equity grants, including RSUs and stock options with vesting schedules tied to continued service, is consistent with compensation practices observed in comparable biotech companies.
• The use of the 2018 Equity Incentive Plan for these grants indicates a pre-established and approved framework for executive and director compensation, similar to plans at companies like BioNTech or Moderna, which utilize equity to incentivize leadership.

Corporate Governance

Related Party Transactions

• The equity grants to Director Laura Hamill constitute a related party transaction, as she is a member of the company's board of directors.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of director's interests with long-term shareholder value through equity ownership.
• Employees: No direct impact mentioned, but general positive signal regarding executive compensation practices.
• Director (Laura Hamill): Positive impact through significant equity compensation, incentivizing continued service and performance.

Next Steps

• Vesting of 25,080 Restricted Stock Units on the earlier of June 30, 2026, or the date immediately preceding the 2026 annual meeting of stockholders.
• Vesting of 33,450 Employee Stock Options in equal monthly installments until June 30, 2026.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, SEC Form 4, Director Compensation, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Insider Transaction, Corporate Governance